Lung Cancer Clinical Trial

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Summary

The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy
ECOG performance status of 0-2
Age > 18 years old
Ability to understand and the willingness to personally sign the written IRB approved informed consent document
Estimated life expectancy of 12 weeks or longer

Exclusion Criteria:

Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist
Age < 18 years old
Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree
Diagnosis of interstitial pulmonary fibrosis
Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

45

Study ID:

NCT06080061

Recruitment Status:

Recruiting

Sponsor:

Stanford University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Stanford University
Palo Alto California, 94305, United States More Info
Kelly Huang
Contact
650-724-4606
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

45

Study ID:

NCT06080061

Recruitment Status:

Recruiting

Sponsor:


Stanford University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.